Revvity ($RVTY) Stock Forecast: Up 5.0% Today

What is Revvity?

Revvity (RVTY) is a healthcare diagnostics and research company focusing on higher-growth, higher-margin areas like life sciences, diagnostics, and software. The stock had a strong bullish movement today, outperforming competitors and closing at $100.30.

Why is Revvity going up?

RVTY stock is up 5.0% on Jun 9, 2026 13:50

• The bullish movement in Revvity's stock can be attributed to the strategic decision to divest its China immunodiagnostics business, aligning with its goal to concentrate on more lucrative sectors like life sciences and software.
• Investors seem to be responding positively to the company's shift towards higher-growth areas, potentially easing concerns about near-term growth and margin pressures.
• Analysts' optimism about Revvity's future revenue and earnings growth, coupled with the overall outperformance of the stock in a mixed trading day, likely contributed to the bullish sentiment.
• Despite facing risks from regulatory changes and a dilution adjustment, the market seems to be focusing on the company's long-term investment narrative and potential upside in the healthcare diagnostics sector.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

How Investors May Respond To Revvity (RVTY) Divesting Its China Immunodiagnostics Business

Revvity (RVTY) plans to divest its China immunodiagnostics business, which previously contributed 6% of its revenue, aligning with its strategy to focus on higher-growth, higher-margin areas like life sciences, diagnostics, and software. This move is expected to reshape investor perception of future earnings quality and mix, potentially easing near-term growth and margin pressures, while still facing risks from regulatory changes in healthcare markets. Despite some analyst concerns regarding China policy risks, the divestiture is viewed as directionally positive for Revvity's long-term investment narrative, which projects significant revenue and earnings growth by 2029.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/how-investors-may-respond-to-revvity-rvty-divesting-its-chin/amp

How Investors May Respond To Revvity (RVTY) Divesting Its China Immunodiagnostics Business

Revvity (RVTY) is divesting its China immunodiagnostics business, which represented about 6% of its revenue, to focus on higher-growth, higher-margin areas. This strategic move aligns with the company's goal to shift towards life sciences, diagnostics, and software, potentially easing near-term growth and margin pressures while managing policy and funding challenges in key healthcare markets. While the divestiture itself may not significantly impact overall near-term revenue trajectory, it is seen as a key indicator for the quality and mix of future earnings.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/how-investors-may-respond-to-revvity-rvty-divesting-its-chin

Revvity Inc. stock outperforms competitors on strong trading day

Revvity Inc. (RVTY) shares rose by 1.96% on a mixed trading day, closing at $100.30. This performance outpaced the broader market, with the S&P 500 Index seeing a modest gain and the Dow Jones Industrial Average experiencing a slight dip. The stock remains 15.22% below its 52-week high of $118.30.

https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-651aace6-b947d9fa1fa4

Revvity, Inc. (RVTY) Stock Analysis: A Compelling 15.53% Upside in the Healthcare Diagnostics Sector

Revvity, Inc. (RVTY), a healthcare diagnostics and research company, shows a potential upside of 15.53% based on recent analyst ratings. With a market cap of $10.97 billion and a current trading price of $98.37, the company offers innovative health sciences solutions with a diverse customer base. Despite mixed financial metrics, analysts are cautiously optimistic, highlighting its strategic focus and growth trajectory in the evolving healthcare landscape.

https://www.directorstalkinterviews.com/revvity-inc-rvty-stock-analysis-a-compelling-15-53-upside-in-the-healthcare-diagnostics-sector/4121253189

Dilution adjustment of Revvity, Inc. – XETR:PKN

This article provides a brief notice about a dilution adjustment for Revvity, Inc., traded on XETRA under the ticker PKN. The content focuses on financial market data and general information about the company's stock, though no specifics of the dilution adjustment are given. The remaining text consists mainly of navigation and footer elements from the source website.

https://www.tradingview.com/symbols/XETR-PKN/financials-income-statement/dilution-adjustment/

Trending Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 5.7% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 6.1% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.7% Today

Petco Health and Wellness Co. Inc. ($WOOF) Stock Forecast: Up 7.7% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 8.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 7.0% Today

Newell Brands Inc. ($NWL) Stock Forecast: Up 7.6% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.8% Today

Penn National Gaming Inc. ($PENN) Stock Forecast: Up 6.7% Today

Sunrun Inc. ($RUN) Stock Forecast: Down 8.0% Today

Revvity Price History

06.04.2026 - RVTY Stock was up 5.3%

• Strong Q1 2026 results were reported by Revvity, surpassing earnings expectations with 3% total company organic growth and improved operating margins, indicating positive financial performance.
• The company's decision to sell its immunodiagnostics business in China in favor of focusing on AI-powered software and operational efficiencies appears to have resonated well with investors, leading to an increase in the stock price.
• A sector-wide rally in medical instruments and supplies, accompanied by significant gains by peers like RVTY, indicates a broader institutional shift towards biomanufacturing and life sciences markets, heightening investor interest in companies like Revvity.
• Overall, Revvity's strategic decisions and strong financial performance were positively received by the market, resulting in a bullish movement in the stock price.

23.03.2026 - RVTY Stock was down 10.0%

• Today's decrease in Revvity Inc. (RVTY) stock price is linked to a widespread selloff in the diagnostics and research industry, affecting other companies like Charles River Laboratories International and MEDP.
• The Vice President of Revvity selling 80 shares through a pre-planned trading scheme may have influenced the negative market sentiment towards the stock.
• Despite the general market downturn, Revvity Inc. demonstrated better performance than its industry counterparts, reflecting resilience in the market.
• Investors could be exercising caution due to uncertainties in the sector, notwithstanding Revvity's strong market position, healthy free cash flow, and positive analyst projections.

30.03.2026 - RVTY Stock was up 5.1%

• Revvity Inc.'s stock displayed strong bullish movement today, despite recent declines, possibly due to investors perceiving the stock as undervalued following its low point.
• The company's robust Q4 2025 financial results, surpassing expectations, likely bolstered investor confidence, contributing to the positive trajectory of the stock.
• Analysts' favorable ratings and optimistic price projections, ranging between $110 and $125, may have enhanced the overall positive sentiment surrounding Revvity Inc.'s stock.
• Recent underperformance of Revvity Inc. compared to industry peers and general market downturns might have presented a buying opportunity for investors, influencing today's bullish movement.

02.05.2026 - RVTY Stock was down 5.4%

• Coverage was initiated on Revvity with a "Peer Perform" rating by Wolfe Research, expressing valuation concerns compared to historical trading patterns.
• Stifel reduced its price target for Revvity to $100 from $110, maintaining a Hold rating after surpassing analyst expectations in Q1 2026.
• Revvity underperformed on a day of market gains, suggesting internal factors influenced the bearish movement.
• The high P/E ratio and moderate GF Score™ of 74/100 raised caution among investors, possibly contributing to the downward pressure on Revvity's stock.

24.03.2026 - RVTY Stock was up 5.1%

• Revvity's stock price rose following the announcement of an anticipated fourth-quarter revenue of $772 million, in line with analyst predictions.
• While other companies in the sector, such as Charles River Laboratories International and MEDP, faced a downturn, Revvity defied the trend and witnessed a bullish trend.
• Investor response to Revvity's revenue forecasts suggests confidence in the company's growth potential despite challenges in the industry.
• The increase in Revvity's stock price may also be due to a reevaluation of the company's prospects amid sector-wide challenges, leading to greater institutional interest and changing investor sentiment.

28.04.2026 - RVTY Stock was up 5.1%

• Revvity's stock experienced a strong bullish movement today, potentially influenced by the initiation of a new share repurchase program following its latest quarterly earnings release.
• Analyst targets and intrinsic value estimates suggest the stock is undervalued, with expectations of margin expansion from product mix shifts and cost actions driving optimism.
• The broader rally in the diagnostics and research sector, as seen with other companies, could have also positively impacted Revvity's stock price.
• Investors are closely monitoring the sector-wide sentiment to determine if the bullish movement in Revvity and its peers will be sustained or if it's a short-term trend.

29.03.2026 - RVTY Stock was down 5.5%

• Revvity Inc.'s stock showed weaker performance compared to its industry counterparts amidst overall market challenges.
• Despite the company's participation in the TD Cowen Healthcare Conference, investor perception did not improve, leading to further stock depreciation.
• A recent downgrade from Barclays, lacking specific explanations, could have contributed to the prevailing negative outlook on Revvity Inc.
• Even with institutional investments from Impax Asset Management Group plc, Revvity Inc.'s stock experienced a notable decline, despite the presence of such investments.

28.04.2026 - RVTY Stock was up 5.2%

• The uptick in RVTY's stock could be linked to the introduction of a new share buyback program post its latest quarterly earnings, showcasing trust in the company's capital allocation strategies.
• Analyst projections and estimates pointing towards undervaluation of the stock might have influenced positive market outlook, anticipating margin growth from shifts in product mix and cost measures.
• A neutral short-term perspective alongside a robust mid-term outlook in the price-driven evaluation may have boosted investor confidence, potentially propelling the stock's upward trend.
• In conclusion, a combination of favorable corporate advancements, indicators of undervaluation, and sentiment analysis likely fed into the positive momentum witnessed in RVTY today.

09.05.2026 - RVTY Stock was up 5.0%

• The bullish movement in Revvity's stock can be attributed to the strategic decision to divest its China immunodiagnostics business, aligning with its goal to concentrate on more lucrative sectors like life sciences and software.
• Investors seem to be responding positively to the company's shift towards higher-growth areas, potentially easing concerns about near-term growth and margin pressures.
• Analysts' optimism about Revvity's future revenue and earnings growth, coupled with the overall outperformance of the stock in a mixed trading day, likely contributed to the bullish sentiment.
• Despite facing risks from regulatory changes and a dilution adjustment, the market seems to be focusing on the company's long-term investment narrative and potential upside in the healthcare diagnostics sector.

05.04.2026 - RVTY Stock was up 5.0%

• The company disclosed its Q1 2026 financial results, reporting revenue of $711 million and surpassing analyst estimates for adjusted EPS. This strong performance likely influenced the bullish movement in the stock.
• Despite exceeding earnings projections, the stock's mixed response could be linked to the company revising down its full-year revenue and adjusted EPS guidance, causing uncertainty among investors.
• The decision to sell off its China Immunodiagnostics business might have boosted investor confidence by streamlining operations and focusing on more profitable segments.
• Management’s positive forecast for FY 2026, including projected adjusted EPS and revenues, may have boosted investor trust and contributed to the stock's bullish movement.

07.04.2026 - RVTY Stock was up 6.4%

• Revvity reported a rise in adjusted earnings and revenue for the first quarter, showcasing a strong financial start to the year.
• An analyst firm maintained a Buy rating on Revvity shares, indicating continued confidence in the company's stock performance.
• The company's strategic decision to divest its immunodiagnostics business in China to accelerate growth and invest in AI-powered platforms contributed to the positive market movement.
• Despite revenue falling short of expectations, the focus on AI investments and operational efficiencies is expected to enhance future performance and capitalize on increased demand in drug discovery, driving investor optimism.

06.04.2026 - RVTY Stock was up 7.3%

• Strong Q1 2026 results were reported by Revvity, surpassing earnings expectations. Additionally, they announced a strategic decision to divest their immunodiagnostics business in China to drive growth and enhance financials.
• The company's emphasis on investing in AI-powered software and operational efficiencies has garnered positive investor sentiment, boosting confidence in potential future performance.
• A sector-wide uptrend in medical instruments and supplies, reflected in peers like RVTY, signifies a larger institutional trend towards biomanufacturing and life sciences markets. This trend has contributed to the stock's bullish movement.